Refractory neuro-Behçet treated by tocilizumab: a case report

CER4917
2012 Vol.30, N°3 ,Suppl.72
PI 0073, PF 0075
Case Reports

Free to view
(click on article PDF icon to read the article)

PMID: 23020826 [PubMed]

Received: 16/07/2011
Accepted : 27/01/2012
In Press: 27/09/2012
Published: 19/11/2012

Abstract

A patient with central nervous system involvement of Behçet`s disease was refractory to conventional immunosuppressive therapy and showed secondary failure of the anti-TNF agent infliximab. This presented as a progressive weakness of the legs and reduction in walking distance. The cerebrospinal fluid showed signs of inflammation including a vastly elevated IL-6 concentration. Given this result, the anti-IL-6 receptor antibody tocilizumab was administered and a good improvement of inflammatory parameters and a satisfactory increase of the walking distance were achieved.